EUCTR2004-002743-27-IT进行中（未招募）不适用
An open-label extension of study TKT024 evaluating long-term safety and clinical outcomes in MPS II patients receiving iduronate-2-sulfatase enzyme replacement therapy.
TKT INC0 个研究点目标入组 94 人开始时间: 2005年8月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement TherapyMucopolysaccharidosis Type II (MPS II or Hunter Syndrome)MedDRA version: 6.1Level: PTClassification code 10056889EUCTR2004-002743-27-SEShire Human Genetic Therapies INC.96
进行中（未招募）
不适用
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement TherapyEUCTR2004-002743-27-DEShire Human Genetic Therapies INC.96
进行中（未招募）
1 期
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement TherapyMucopolysaccharidosis Type II (MPS II or Hunter Syndrome)MedDRA version: 6.1Level: PTClassification code 10056889EUCTR2004-002743-27-GBTKT Inc.94
进行中（未招募）
1 期
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement TherapyMucopolysaccharidosis Type II (MPS II or Hunter Syndrome)MedDRA version: 6.1Level: PTClassification code 10056889EUCTR2004-002743-27-ESTKT Inc.94
进行中（未招募）
1 期
Follow on study in adult Fabry Disease patientsFabry diseaseMedDRA version: 14.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2009-015985-75-SIShire Human Genetic Therapies (HGT), Inc.43